Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Largely because of disparities in access to drug treatment and
care, AIDS morbidity and mortality have fallen in the developedworld
but continue to rise among developing countries. Achievingmore
equitable access to AIDS drugs is hindered by high drug prices,technical complexities related to the provision of health care,and
conflict among stakeholders. Recognition that health is vitalto the
prospects of the emerging global society must be combinedwith new
mechanisms to help all stakeholders work together cooperatively.Tiered
drugs pricing should be coupled with investment in healthservices.
An independent "Global Task Force," able to act as an"active
think tank," could build consensus about the way forward.
1 Department of Population and International Health,
School of Public Health, Harvard University, Boston, MA 02115, USA.
E-mail: dbloom{at}hsph.harvard.edu 2 61a West Borough,
Wimborne, Dorset BH 21 1LX, UK. E-mail: pathfinders{at}riverpath.com
